A Review: Divergent Emerging Strategies to Tackle Challenging Covid-19
Background: Contemplating the severity of pandemic sequel for public health many researchers are working recklessly for new targeted drugs and vaccines. Despite the challenging opportunities, the setup for the development of new effective remedy against COVID-19 is unforeseeable.
Objective: The aim of the present review was to explore the work done by some authors to battle against COVID-19.
Material & Method: We analysed 24 articles from Elsevier and one from J Med virology journals stating different strategies to cope with this recently arrived monster COVID-19. Further are some targeting therapies viz., Niclosamide, immune response generated by cytotoxic T-cells and Natural Killer cells, Chloroquine and Hydroxy Chloroquine, blockade of Interleukin17, N- Acetylcysteine, mucolytic agents, oxytocin, bioflavonoids, triterpenoid saponins, ACE inhibitors or AII receptor antagonists, Hyperbaric oxygen therapy, serum albumin, Ritonavir, Tocilizumab, Furin, Amantadine, pioglitazone, Dapsone and doxycycline, steroids, plasama therapy, routine childhood immunization, a data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS corona viral infection, lipid metabolism has been proposed as a treatment target for COVID-19, COVIDiagnosis-Net proposed network for quick and accurate diagnosis.
Result: We got to know how the people are struggling to find a cure for this pandemic affair.
Conclusion: Till date, there is no specific treatment that has been confirmed to the effect against COVID-19. Let’s hope for the best.
Key words: COVID-19, Novel Corona Virus Infection-2019, SARS-CoV2, Plasma therapy, Immunomodulators
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z, “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China” JAMA, 2020; 323(11):1061-1069.
3. Pindiprolu SKSS and Pindiprolu SH, “Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19” Med Hypotheses, 2020; 140:109765.
4. Yaqinuddin A and Kashir J, “Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents” Med Hypotheses, 2020; 140:109777.
5. Sargina G, Yavaşoğlu SI, Yavasoglu I, “Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?” Med Hypotheses, 2020; 140:109756.
6. Megna M, Napolitano M, Fabbrocinia G, “May IL-17 have a role in COVID-19 infection?” Med hypothesis, 2020; 140: 109749.
7. Adamowicz J, Juszczak K, Drewa T, “May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19complications?” Med Hypotheses, 2020; 140:109751.
8. Assimakopoulos SF and Marangos M, “N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome” Med Hypotheses, 2020; 140:109778.
9. Soumier A and Sirigu A, “Oxytocin as a potential defence against Covid-19?” Med Hypotheses, 2020; 140: 109785.
10. Coppolaa M and Mondolab R, “Phototherapeutics and SARS-CoV-2 infection: Potential role of bioflavonoids” Med Hypotheses, 2020; 140: 109766.
11. Bahbah EI, Negida A, Nabet MS, “Purposing Saikosaponins for the treatment of COVID-19” Med Hypotheses, 2020; 140:109782.
12. Roncati L, Gallo G, Manenti A, Palmieri B, “Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2” Med hypothesis, 2020; 140: 109686.
13. Geier MR and Geier DA, “Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality” Med hypothesis, 2020; 140:109760.
14. Salmana S and Salemb ML, “Routine childhood immunization may protect against COVID-19” Med hypotheses, 2020; 140:109689.
15. Mishra PM, Uversky VN, Nandi CK, “Serum albumin-mediated strategy for the eﬀective targeting of SARS-CoV-2” Mel Hypothesis, 2020; 140: 109790.
16. Choudhurya S and Mazumderb MK, “Suggesting Ritonavir against COVID-19/SARS-CoV-2” Med hypothesis, 2020; 140:109764.
17. Salem ML and El-Hennawy D, “The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19” Med hypothesis, 2020; 140:109752.
18. Silberstein M, “Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?” Med Hypotheses, 2020; 140:109767.
19. Afsar CU, “2019-nCoV-SARS-CoV-2 (COVID-19) infection: Crucıalıty of Furın and relevance wıth cancer” Med Hypotheses, 2020; 140:109770.
20. Abreu GEA, Aguilar MEH, Covarrubias DH, Durán FR, “Amantadine as a drug to mitigate the eﬀects of COVID-19” Med Hypotheses, 2020; 140: 109755.
21. Carboni E, Carta AR, Carboni E, “Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?” Med Hypotheses, 2020; 140:109776.
22. Brenner SR, “Covid-19, TMPRSS2, and whether android regulation aﬀects pandemic virus gender incidence and age distribution of disease” Med Hypotheses, 2020; 140:109773.
23. Farouka A and Salmanb S, “Dapsone and doxycycline could be potential treatment modalities for COVID-19” Med Hypotheses, 2020; 140:109768.
24. Karaahmeta F and Karaahmetb OZ, “Potential effect of natural and anabolizan steroids in elderly patient with COVID-19” Med Hypotheses, 2020; 140:109772.
25. Vavougios GD, “A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS corona viral infection: Potential implications for the SARS-CoV-2 modus operandi” Med Hypotheses, 2020; 140:109759.
26. Ucara F and Korkmazb D, “COVIDiagnosis-Net: Deep Bayes-SqueezeNet based diagnosis of the coronavirus disease 2019 (COVID-19) from X-ray images” Med Hypotheses, 2020; 140:109761.
27. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T, “Treatment with convalescent plasma for COVID-19 patients in Wuhan, China” J Med virology, 2020; https://doi.org/10.1002/jmv.25882.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).